Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 31

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Free Fatty Acid Receptor 4 - Pipeline Review, H1 2018'; Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) pipeline Target constitutes close to 9 molecules.

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Free Fatty Acid Receptor 4 is a G protein-coupled receptor (GPR) encoded by FFAR4 gene. It acts as receptor for medium and long-chain free fatty acids (FFAs). It acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G (q)/G (11)-coupled pathway. It mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. It mediates the taste of fatty acids.

The report 'Free Fatty Acid Receptor 4 - Pipeline Review, H1 2018' outlays comprehensive information on the Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 6 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Type 2 Diabetes, Unspecified, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4)

- The report reviews Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Overview
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Companies Involved in Therapeutics Development
AstraZeneca Plc
CymaBay Therapeutics Inc
Dompe Farmaceutici SpA
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co Inc
Sancilio & Company Inc
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Drug Profiles
CB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-137647A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FFAR4 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR120 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FFA4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR-120 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR120 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR120 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by CymaBay Therapeutics Inc, H1 2018
Pipeline by Dompe Farmaceutici SpA, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Sancilio & Company Inc, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 -- Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Metabolic, Musculoskeletal), Channel (Hospital Pharmacy, Retail Pharmacy, E-commerce)
    Published: 25-Jun-2018        Price: US 2400 Onwards        Pages: 240
    Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Sterile Injectables Market by Molecule Type (Biologic, Small Molecule),  Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Met......
  • Global Erythropoietin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Erythropoietin Market 2018, Forecast to 2023
    Published: 23-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global Burkitt Lymphoma Treatment Market Research Report 2018
    Published: 22-Jun-2018        Price: US 2900 Onwards        Pages: 96
    This report studies the global Burkitt Lymphoma Treatment market status and forecast, categorizes the global Burkitt Lymphoma Treatment market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Burkitt Lymphoma Treatment market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of duri......
  • Global Vegetable Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vegetable Capsules Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global Sugar Sphere Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sugar Sphere Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 132
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Tyrosinase Market Research Report 2018
    Published: 22-Jun-2018        Price: US 2900 Onwards        Pages: 95
    This report studies the global Tyrosinase market status and forecast, categorizes the global Tyrosinase market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Tyrosinase market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major manufactu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs